NEWS

NEWS

Total 102

82
QUARTERLY UPDATE (Q2 2023)
2023-07-05
81
NeoImmuneTech and NIAID Embark on a Collaborative Study to Explore New Treatment for Acute Radiation Syndrome (ARS)
2023-06-20
80
QUARTERLY UPDATE (Q1 2023)
2023-04-05
79
First Patient Dosed in Phase II Study of NeoImmuneTech’s NT-I7 plus Pembrolizumab in Recurrent Glioblastoma
2023-02-07
78
QUARTERLY UPDATE (Q4 2022)
2023-01-06
77
NeoImmuneTech to Partner with U.S. National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) for Drug Development in Acute Radiation Syndrome (ARS)
2023-01-03
76
Pharmaphorum highlights NeoImmuneTech
2022-12-19
75
NeoImmuneTech to Present at 2023 Biotech Showcase
2022-12-15
74
New evidence of NeoImmuneTech’s NT-I7 clinical efficacy in combination with pembrolizumab in relapsed/refractory (r/r) gastrointestinal tumors
2022-11-14
73
NeoImmuneTech to Present First Data on NT-I7 (efineptakin alfa) in Combination with CAR-T tisagenlecleucel, at 2022 ASH Annual Meeting
2022-11-04

1 2 3 4 5 >>>